IPCALAB - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.6
| Stock Code | IPCALAB | Market Cap | 35,805 Cr. | Current Price | 1,410 ₹ | High / Low | 1,595 ₹ |
| Stock P/E | 37.0 | Book Value | 292 ₹ | Dividend Yield | 0.28 % | ROCE | 17.6 % |
| ROE | 12.6 % | Face Value | 1.00 ₹ | DMA 50 | 1,443 ₹ | DMA 200 | 1,410 ₹ |
| Chg in FII Hold | 0.20 % | Chg in DII Hold | 0.54 % | PAT Qtr | 305 Cr. | PAT Prev Qtr | 262 Cr. |
| RSI | 41.4 | MACD | -6.80 | Volume | 1,22,653 | Avg Vol 1Wk | 2,19,550 |
| Low price | 1,168 ₹ | High price | 1,595 ₹ | PEG Ratio | -50.6 | Debt to equity | 0.11 |
| 52w Index | 56.6 % | Qtr Profit Var | 24.8 % | EPS | 30.3 ₹ | Industry PE | 29.1 |
📊 Analysis: IPCALAB is trading at ₹1,410, right at its 200 DMA and slightly below its 50 DMA (₹1,443), indicating neutral to mildly bearish technicals. RSI at 41.4 suggests the stock is approaching oversold territory, while MACD at -6.80 confirms weak momentum. Current volume (1.22 lakh) is lower than the 1-week average (2.19 lakh), showing reduced intraday participation. Fundamentals remain solid with ROCE 17.6% and ROE 12.6%, supported by quarterly PAT growth. Intraday opportunities exist for cautious traders near support levels.
💡 Optimal Buy Price: ₹1,405–₹1,415 (near support zone).
🎯 Profit-Taking Levels: ₹1,435–₹1,445 (short-term resistance).
🛡️ Stop-Loss: ₹1,390 (to protect against downside risk).
⏱️ Exit Strategy if Already Holding: Exit if price fails to sustain above ₹1,410 with weakening momentum or if volume continues to decline. If intraday rebound occurs, consider booking profits around ₹1,435–₹1,445. Avoid holding beyond resistance unless strong breakout signals appear.
✅ Positive
- Quarterly PAT growth (₹305 Cr vs ₹262 Cr) shows improving profitability.
- Strong EPS of ₹30.3 reflects earnings capability.
- ROCE 17.6% and ROE 12.6% indicate healthy efficiency.
- Institutional support with FII (+0.20%) and DII (+0.54%) stake increases.
- Low debt-to-equity ratio (0.11) ensures financial stability.
⚠️ Limitation
- Trading below 50 DMA and at 200 DMA, showing weak technical strength.
- MACD negative (-6.80), signaling bearish momentum.
- High P/E of 37 compared to industry PE of 29.1, suggesting overvaluation.
- Volume lower than 1-week average, limiting intraday strength.
- PEG ratio (-50.6) reflects poor growth relative to valuation.
📉 Company Negative News
- Stock corrected from 52-week high of ₹1,595 to current ₹1,410.
- Weak technical indicators with bearish undertone.
📈 Company Positive News
- Quarterly profit variation shows 24.8% growth YoY.
- EPS and book value (₹292) provide strong fundamental support.
- Institutional investors increasing stake, showing confidence.
🏭 Industry
- Industry PE at 29.1 is lower than IPCALAB’s PE of 37, highlighting relative overvaluation.
- Pharma sector remains resilient with steady demand outlook.
🔎 Conclusion
IPCALAB shows strong fundamentals but weak technicals in the short term. For intraday trading, cautious buying near support with tight stop-loss is advisable. Quick profit booking around resistance levels is optimal, as momentum indicators remain bearish. The stock is better suited for tactical trades rather than aggressive intraday positions.